STOCK TITAN

Theravance Bioph - TBPH STOCK NEWS

Welcome to our dedicated page for Theravance Bioph news (Ticker: TBPH), a resource for investors and traders seeking the latest updates and insights on Theravance Bioph stock.

Overview of Theravance Biopharma Inc

Theravance Biopharma Inc (NASDAQ: TBPH) is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. With a solid foundation built on internally discovered product candidates and strategic partnerships, the company has positioned itself as a key player in addressing critical unmet needs in the treatment of respiratory and neurological disorders. Utilizing advanced research methodologies and precision medicine approaches, Theravance Biopharma aims to maximize therapeutic efficacy while minimizing systemic side effects.

Core Business and Product Portfolio

At its core, Theravance Biopharma invests heavily in the development of small-molecule drugs designed for organ-selective targeting. This strategy is exemplified by its FDA-approved product, YUPELRI (revefenacin) inhalation solution, which is the first and only once-daily nebulized long-acting muscarinic antagonist (LAMA) approved for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). The company’s approach in leveraging organ-selectivity not only underpins its ability to deliver sustained improvements in pulmonary function but also highlights its commitment to addressing patient-specific needs through enhanced treatment outcomes.

Innovative Research and Development Strategy

Theravance Biopharma distinguishes itself through a robust, internally focused research and development platform. The company pioneers a new generation of small molecule drugs by applying its expertise in organ-selectivity to target diseases biologically. This approach is particularly significant in the field of inflammation and immunology where therapeutic indices can be expanded, thereby maximizing benefits while reducing systemic exposure. In addition to YUPELRI, the company is advancing a pipeline of promising product candidates, including ampreloxetine—an investigational agent developed as a once-daily norepinephrine reuptake inhibitor intended to manage symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy (MSA).

Strategic Collaborations and Market Position

Theravance Biopharma’s operational strategy is enhanced by strategic collaborations with other pharmaceutical companies. These partnerships not only complement the company’s internal discovery efforts but also provide additional avenues to accelerate clinical development, expand market reach, and optimize commercialization strategies. The unique collaboration dynamics, such as those with global commercial partners, reinforce the company’s capacity to navigate the competitive landscape and address market challenges effectively, making it a significant entity within the biopharmaceutical sector.

Expertise and Industry Credibility

The company’s demonstrated ability to innovate in the field of organ-selective medicine reflects deep scientific expertise and rigorous research methodologies. By combining academic research, clinical insights, and regulatory know-how, Theravance Biopharma has established a reputation for both innovation and reliability in its therapeutic niche. The consistent focus on delivering measurable clinical benefits, backed by peer-reviewed studies and rigorous clinical trial designs, further enhances its authority within the competitive landscape of respiratory and neurological therapeutics.

Comprehensive Business Model and Value Proposition

Theravance Biopharma’s business model revolves around the development and commercialization of a targeted portfolio that maximizes therapeutic efficacy while addressing market needs through innovative medicine. The company’s dual focus on an approved, commercially successful product and a robust pipeline of candidate drugs positions it well within its market segment. Although complex market dynamics and regulatory challenges exist, its disciplined approach to research and clinical development reinforces its stand as a scientifically driven enterprise dedicated to creating medicines that make a difference.

Investor and Market Insights

For investors and market researchers, Theravance Biopharma represents a blend of innovative research coupled with a commercially validated product. Its trajectory showcases an interplay between internally driven discovery and collaborative strength, which is reflected in its ever-expanding clinical developments and its focused approach toward addressing diseases with significant unmet patient needs. The company continually refines its research and development strategies, ensuring that its product portfolio remains both relevant and robust in an evolving therapeutic landscape.

Rhea-AI Summary

Theravance Biopharma (NASDAQ: TBPH) will participate in the 43rd Annual TD Cowen Health Care Conference on March 8, 2023, at 10:30 am ET. The event will include a Respiratory/Infections Corporate Panel Discussion.

The conference will be accessible via webcast on Theravance.com, where a replay will be available for 30 days. Theravance Biopharma is known for its FDA-approved YUPELRI® inhalation solution for COPD and is developing Ampreloxetine, targeting neurogenic orthostatic hypotension. The firm's commitment is towards improving patient lives and increasing shareholder value.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
conferences
-
Rhea-AI Summary

Theravance Biopharma (TBPH) has announced significant strategic moves, including increasing its capital return program from $250 million to $325 million. As of February 27, 2023, approximately $170 million remains in this program. The company reported $19.5 million in YUPELRI® sales for Q4 2022, a 27% year-over-year increase, marking its strongest quarter. Additionally, Theravance will discontinue research investments and reduce headcount by 17% to focus resources on the ampreloxetine Phase 3 study. The company reaffirmed its guidance for non-GAAP profitability in the second half of 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
-
Rhea-AI Summary

Irenic Capital Management, a major shareholder of Theravance Biopharma (NASDAQ: TBPH), criticized the company's leadership and called for strategic changes. Since its separation in 2014, Theravance's total shareholder return has plummeted by -50%, reflecting a significant discount in its market value. Irenic proposed actions such as returning $300 million in excess cash to shareholders, reducing operational costs, and improving governance by appointing a shareholder representative. They estimate that adopting these measures could unlock nearly $21 per share in value, substantially higher than its current trading price of $9.87.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.99%
Tags
none
Rhea-AI Summary

Theravance Biopharma (TBPH) will announce its fourth quarter and full-year 2022 financial results on February 27, 2023, after market close. A conference call and webcast are scheduled for 5:00 PM ET on the same day, allowing investors to gain insights into the company's performance. Interested parties can participate by pre-registering online. The company is known for its FDA-approved drug, YUPELRI, aimed at treating COPD and continues to focus on developing new therapies for unmet medical needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.59%
Tags
conferences earnings
-
Rhea-AI Summary

Theravance Biopharma (NASDAQ: TBPH) will participate in a Fireside Chat at the SVB Securities Global Biopharma Conference on February 15, 2023, at 8:00 am ET. The event can be accessed via a webcast on Theravance.com in the Investors section. A replay will be available for 30 days post-event. Theravance Biopharma is committed to delivering Medicines that Make a Difference and is known for its FDA-approved YUPELRI® inhalation solution for COPD. The company focuses on addressing significant unmet patient needs through its innovative pipeline.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
conferences
-
Rhea-AI Summary

Theravance Biopharma (TBPH) announced significant 2022 achievements and 2023 objectives. Key highlights include strategic advances in YUPELRI sales growth, with all-time high net sales reported in Q2 and Q3. The company initiated the Phase 3 CYPRESS study for ampreloxetine in patients with symptomatic neurogenic orthostatic hypotension (nOH) planned for Q1 2023, alongside a $250 million capital return program. With FDA discussions and a $1.1 billion royalty sale, Theravance aims for Non-GAAP profitability by 2H 2023, reinforcing its commitment to delivering impactful medicines.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.96%
Tags
none
Rhea-AI Summary

On November 22, 2022, Theravance Biopharma (NASDAQ: TBPH) announced the final results of its Dutch auction tender offer, which aimed to purchase up to $95 million of its ordinary shares. The offer expired on November 17, 2022, with a total of 115,967 shares tendered and accepted at $10.50 each, totaling approximately $1.2 million. This amount represents about 0.2% of the shares outstanding. The company plans to use the unused funds for an open market share repurchase program expected to commence after the tender offer's completion.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.2%
Tags
none
-
Rhea-AI Summary

Theravance Biopharma (NASDAQ: TBPH) announced the preliminary results of its Dutch auction tender offer, intending to purchase up to $95 million of ordinary shares. The offer expired on November 17, 2022, with 115,967 Shares tendered. The company plans to purchase these shares at $10.50 each, totaling approximately $1.2 million. This represents about 0.2% of the total shares outstanding. Additionally, the unused portion of the offer will fund an open market share repurchase plan expected to begin after the tender offer concludes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.32%
Tags
none
-
Rhea-AI Summary

Theravance Biopharma (NASDAQ: TBPH) reported a record quarter for YUPELRI® (revefenacin) with Q3 2022 net sales reaching $18.7 million, a 35% increase year-over-year. The company completed a significant transaction selling TRELEGY ELLIPTA royalty rights to Royalty Pharma for $1.1 billion in upfront cash and potential milestones. With a strong cash position of $487 million, Theravance is debt-free and initiated a $250 million capital return program. R&D expenses decreased significantly to $9.9 million, while total revenue for Q3 was $12.5 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.08%
Tags
Rhea-AI Summary

Theravance Biopharma (NASDAQ: TBPH) announced promising Phase 3 results for its investigational drug, Ampreloxetine, targeting neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA). Data presented at the 33rd International Symposium on the Autonomic Nervous System shows significant symptom improvement across multiple scales compared to placebo. Ampreloxetine demonstrated a similar safety profile to placebo, with no significant adverse effects. The company plans to initiate a new registrational Phase 3 study in early 2023, aiming to file for NDA with the FDA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.9%
Tags
none

FAQ

What is the current stock price of Theravance Bioph (TBPH)?

The current stock price of Theravance Bioph (TBPH) is $9.02 as of April 1, 2025.

What is the market cap of Theravance Bioph (TBPH)?

The market cap of Theravance Bioph (TBPH) is approximately 446.0M.

What is Theravance Biopharma's core business?

Theravance Biopharma focuses on the discovery, development, and commercialization of organ-selective medicines. Its strategy centers on creating small-molecule drugs that maximize efficacy and minimize systemic side effects.

What key products does the company offer?

The company’s flagship product is YUPELRI, an FDA-approved, once-daily nebulized long-acting muscarinic antagonist for COPD maintenance. Additionally, it is advancing ampreloxetine in its pipeline for neurological indications.

How does Theravance Biopharma generate revenue?

Revenue is primarily generated through the commercialization of its approved product, YUPELRI, and through strategic collaborations that bolster its clinical development and market reach.

What distinguishes its research and development strategy?

Theravance Biopharma applies organ-selective targeting to enhance the therapeutic index of its medicines. Its robust internal discovery engine, combined with strategic partnerships, underpins its innovative R&D approach.

How does the company maintain its industry credibility?

The company leverages decades of research, peer-reviewed clinical studies, and rigorous trial designs, all of which reinforce its scientific expertise and build trust within the medical and investor communities.

What are the potential challenges it faces?

Challenges include navigating regulatory requirements, managing clinical trial complexities, and addressing competitive pressures. However, its strategic collaborations and focused R&D provide a strong foundation to meet these challenges.
Theravance Bioph

Nasdaq:TBPH

TBPH Rankings

TBPH Stock Data

445.98M
46.39M
6.22%
93.64%
7.54%
Biotechnology
Pharmaceutical Preparations
Link
United States
GEORGE TOWN, GRAND CAYMAN